Compare CEVA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CEVA | CGEM |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 573.9M | 671.7M |
| IPO Year | 2000 | 2021 |
| Metric | CEVA | CGEM |
|---|---|---|
| Price | $22.77 | $11.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $34.00 | $28.00 |
| AVG Volume (30 Days) | 570.6K | ★ 1.0M |
| Earning Date | 02-12-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $107,530,000.00 | N/A |
| Revenue This Year | $4.34 | N/A |
| Revenue Next Year | $13.26 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.55 | N/A |
| 52 Week Low | $18.23 | $5.68 |
| 52 Week High | $38.94 | $13.33 |
| Indicator | CEVA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 52.93 | 59.12 |
| Support Level | $21.10 | $9.41 |
| Resistance Level | $24.01 | $10.70 |
| Average True Range (ATR) | 0.65 | 0.60 |
| MACD | 0.28 | 0.02 |
| Stochastic Oscillator | 65.61 | 92.61 |
CEVA Inc is a licensor of signal-processing intellectual property. Through partnerships with semiconductor companies and original equipment manufacturers globally, the company helps produce devices for a range of end markets. OEMs and semiconductor companies choose to sell products with CEVA equipment to wireless, consumer, automotive, and Internet of Things companies. Revenue is derived primarily from licensing fees and related revenue, and royalties generated from the shipments of products utilizing its intellectual properties. CEVA also engages in the training and sale of development systems.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.